Login to Your Account



NewCo News: Tocagen Gives High-Grade Glioma the One-Two Punch

By Catherine Shaffer


Wednesday, June 8, 2011
A Phase I/II trial of an unusual two-part therapeutic for brain cancer is under way, according to Tocagen Inc. The San Diego-based company has already dosed its first patient cohort, at the first dose, and received a green light from an independent data monitoring committee to progress to the second dose.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription